Biopsy Positivity in Prostate Cancer Patients Undergoing MpMRI-Targeted Radiation Dose Escalation

Radiation (RT) dose escalation improves prostate cancer outcomes, but when the whole gland is treated to high doses complications can arise. In prospective clinical trials, prostate multiparametric MRI (mpMRI) findings were used for targeted tumor dose escalation (MTDE). Since biopsy positivity is a known predictor of biochemical failure, prostate biopsy 2-3 years after completion of RT was planned for all patients treated with such dose escalation. Biopsy positivity of these MTDE patients are compared to those in another cohort in which standard whole gland RT doses were used.

Source: International Journal of Radiation Oncology * Biology * Physics - September 10, 2020 Category: Radiology Authors: Jessica Meshman, Benjamin Farnia, Radka Stoyanova, Isildinha Reis, Matthew Abramowitz, Alan Dal Pra, Eric Horwitz, Alan Pollack Source Type: research